AZD1208

AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor[1].

Product Specifications

CAS Number

[1204144-28-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; Pim

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZD1208.html

Purity

99.73

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC/1=O)SC1=C/C2=C(N3C[C@H](N)CCC3)C(C4=CC=CC=C4)=CC=C2

Molecular Formula

C21H21N3O2S

Molecular Weight

379.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22 (14) :4599-604.|[2]Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205.|[3]Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6 (35) :37930-47.